Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces Financial Results for Q4 and Full Year 2024
Summary
Praxis Precision Medicines, Inc. announced its financial results for the quarter and full year ended December 31, 2024, revealing a cash position of $469.5 million as of December 31, 2024, up from $81.3 million the previous year. The company reported a net loss of $58.7 million for Q4 2024 and $182.8 million for the full year, with increased research and development expenses due to advancements in their Cerebrum platform and increased personnel costs. The company remains focused on its development programs and anticipates key milestones in 2025.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement